QUINOBIOTIC Caplet

Ciprofloxacin is highly effective against bacteria which are resistant to other antibiotic，inclnding aminoglycosides，penicillins, cephalosporin and tetracyclines.

・Mild to moderate urinary tract infections: 250 mg twice daily.

・Severe urinary tract infections : 500 mg twice daily.

・Mild to moderate respiratory tract， bones， joint， skin and soft tissue infections : 500 mg twice daily.

・Severe respiratory tract， bones， joint， skin and soft tissue infections : 750 mg twice daily.

・Gastrointestinal tract infections : 500 mg twice daily.

・Acute gonorrhoea : 250 mg as a single dose

・To achieve adequate concentrations in acute osteomyelitis， the dosage should not be less than 750 mg twice daily

• Patients who are hypersensitive to ciprofloxacin and other quinolone derivatives

• Pregnant and lactation woman，

• Children and growing adolescence.

Quinobiotic is usually well tolerated. Only mild disturbances have been reported:

・Gastrointestinal tract : Nausea， diarrhoea， vomiting, dyspepsia，abdominal pain， flatulence and anorexia.

・Central Nervous System: Dizziness， headache， tiredness and sometimes visual disturbances.

・Skin reactions

・Transient increase in liver enzymes，particularly in patients with previous liver damage.

Inform the doctor if side effects occur.

Concurrent administration of ciprofloxacin with antacids containing aluminium and magnesium may interfere the absorption of ciprofloxacin.

Therefore ciprofloxacin should be taken 1 - 2 hours before or at least 4 hours after the administration of antacids.

Increased plasma levels of theophylline have been observed following concurrent administration with ciprofloxacin. It is recommended that the dose of theophylline should be reduced and plasma levels of theophylline monitered. If concurrent use with theophylline is unavoidable, the serum concentration of theophylline should be checked and the theophylline dosage reduced accordingly

Any possibility of interaction in simultaneous administration of ciprofloxacin with probenecid， clindamycin and metronidazole should be considered.

Inhibition of bacterial DNA gyrase